Who Paid My Doc
David Provenzano
Interventional Pain Medicine Sewickley, PA Medical Doctor
NPI 1790796233 CMS profile 172676
301 Ohio River Blvd Ste 203, Sewickley, PA 15143
General payments
$197,796
Research payments
$38,460
Ownership & investment interest
$0
Research they led as principal investigator
$954,350
Through program year 2025, David Provenzano of Sewickley, PA is reported in the CMS Open Payments database as having received $197,796 across 330 general payments and $38,460 in research payments paid to them. Separately, studies naming them as principal investigator received $954,350 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $23,877 | 55 | |
| 2024 | General | $31,834 | 78 | |
| 2024 | Research | $38,460 | 11 | |
| 2023 | General | $18,883 | 35 | |
| 2022 | General | $24,209 | 45 | |
| 2021 | General | $23,254 | 40 | |
| 2020 | General | $33,551 | 27 | |
| 2019 | General | $42,188 | 50 |
Beside peers
- David Provenzano
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to David Provenzano were reported at $23,877. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | David Provenzano | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $42,188 | $684 | $216–$2,079 | $163 |
| 2020 | $33,551 | $382 | $122–$1,109 | $114 |
| 2021 | $23,254 | $552 | $167–$1,554 | $132 |
| 2022 | $24,209 | $605 | $187–$1,924 | $149 |
| 2023 | $18,883 | $671 | $195–$1,915 | $160 |
| 2024 | $31,834 | $684 | $206–$1,837 | $164 |
| 2025 | $23,877 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
1,406
Drug cost
$20,515
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 456 | $5,858 | |
| Buprenorphine | Generic | 15 | $3,966 | |
| Duloxetine Hcl | Generic | 191 | $3,194 | |
| Pregabalin | Generic | 156 | $2,231 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 132 | $1,430 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 174 | $1,333 | |
| Naloxone Hcl | Generic | 13 | $1,041 | |
| Oxycodone Hcl | Generic | 52 | $454 | |
| Baclofen | Generic | 17 | $204 | |
| Meloxicam | Generic | 61 | $154 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 46 billing codesPaid by Medicare
$106,137
Medicare patients
364
Services billed
2,101
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 29% | |
| Diabetes | 24% | |
| Depression | 24% | |
| Osteoporosis | 17% | |
| Chronic kidney disease | 16% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 15 | 760 | $74 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
341 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Pennsylvania
Michael Fishman
Interventional Pain Medicine · Lebanon, PA
Michael Farrell
Interventional Pain Medicine · Pittsburgh, PA
Farshad Rashidian
Interventional Pain Medicine · West Chester, PA
Chad Metzger
Interventional Pain Medicine · Darby, PA
Jorge Rivero-Becerra
Interventional Pain Medicine · Pittsburgh, PA
James Bresnahan
Interventional Pain Medicine · Springfield, PA
Related records
Interventional Pain Medicine in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.